Prevalence of leukoencephalopathy and its potential cognitive sequelae in cancer patients

References

• Schagen SB, Muller MJ, Boogerd W, Rosenbrand RM, van Rhijn D, Rodenhuis S, van Dam FSAM. Late effects of adjuvant chemotherapy on cognitive function: A follow-up study in breast cancer patients. Ann Oncol. 2002;13(9):1387–97.
   PubMed Web of Science ®Google Scholar
• Seigers R, Fardell JE. Neurobiological basis of chemotherapy-induced cognitive impairment: A review of rodent research. Neurosci Biobehav Rev. 2011;35(3):729–41.
   PubMed Web of Science ®Google Scholar
• de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, Caan M, Douaud G, Lavini C, Linn SC, Boven E, van Dam FSAM, et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: Converging results from multimodal magnetic resonance imaging. Hum Brain Mapp. 2012;33(12):2971–83.
   PubMed Web of Science ®Google Scholar
• Koppelmans V, Breteler MMB, Boogerd W, Seynaeve C, Gundy C, Schagen SB. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. JCO. 2012;30(10):1080–6.
   PubMed Web of Science ®Google Scholar
• Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol. 2008;19(4):623–9.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Jung SO, Kim H, Abraham I. Systematic review of longitudinal studies on chemotherapy-associated subjective cognitive impairment in cancer patients. Psychooncology. February 2020; 29:617–631.
   PubMed Web of Science ®Google Scholar
• Deprez S, Kesler SR, Saykin AJ, Silverman DHS, de Ruiter MB, McDonald BC. International cognition and cancer task force recommendations for neuroimaging methods in the study of cognitive impairment in Non-CNS cancer patients. J Natl Cancer Inst. 2018;110(3):223–31.
   PubMedGoogle Scholar
• Soussain C, Ricard D, Fike JR, Mazeron J-J, Psimaras D, Delattre J-Y. CNS complications of radiotherapy and chemotherapy. Lancet. 2009;374(9701):1639–51.
   PubMed Web of Science ®Google Scholar
• Ahles TA, Root JC. Cognitive effects of cancer and cancer treatments. Annu Rev Clin Psychol. 2018;14(5):1–527.
   PubMedGoogle Scholar
• Ikonomidou C. Chemotherapy and the pediatric brain. Mol Cell Pediatr. 2018;5(1):8.
   PubMedGoogle Scholar
• Cabaj A, Bekiesińska-Figatowska M, Duczkowska A, Duczkowski M. Brain MRI findings in neurological complications of cancer treatment. Adv Clin Exp Med. 2016;25(4):789–97.
   PubMed Web of Science ®Google Scholar
• Lim Y-J, Kim H-J, Lee Y-J, Seol I-J, Lee Y-H. Clinical features of encephalopathy in children with cancer requiring cranial magnetic resonance imaging. Pediatr Neurol. 2011;44(6):433–8.
   PubMed Web of Science ®Google Scholar
• Morris EB, Laningham FH, Sandlund JT, Khan RB. Posterior reversible encephalopathy syndrome in children with cancer. Pediatr Blood Cancer. 2007;48(2):152–9.
   PubMed Web of Science ®Google Scholar
• Matute C, Ransom BR. Roles of white matter in central nervous system pathophysiologies. ASN Neuro. 2012;4(2):AN20110060–101.
   Web of Science ®Google Scholar
• Tang EYH, Amiesimaka O, Harrison SL, Green E, Price C, Robinson L, Siervo M, Stephan BC. Longitudinal effect of stroke on cognition: A systematic review. J Am Heart Assoc. 2018;7(2):e006443.
   PubMed Web of Science ®Google Scholar
• Saa JP, Tse T, Baum C, Cumming T, Josman N, Rose M, Carey L. Longitudinal evaluation of cognition after stroke – A systematic scoping review. PLoS One. 2019;14(8):e0221735.
   PubMed Web of Science ®Google Scholar
• Brainin M, Tuomilehto J, Heiss W-D, Bornstein NM, Bath PMW, Teuschl Y, Richard E, Guekht A, Quinn T, Post Stroke Cognition Study Group. Post-stroke cognitive decline: An update and perspectives for clinical research. Eur J Neurol. 2015;22(2):229–38.
   PubMed Web of Science ®Google Scholar
• Fonseca Wald ELA, Hendriksen JGM, Drenthen GS, Kuijk SMJV, Aldenkamp AP, Vles JSH, Vermeulen RJ, Debeij-van Hall MHJA, Klinkenberg S. Towards a Better Understanding of Cognitive Deficits in Absence Epilepsy: a Systematic Review and Meta-Analysis. Neuropsychol Rev. 2019;29(4):421–49.
   PubMed Web of Science ®Google Scholar
• Malkki H. Cerebrovascular disorders: Cerebral microbleeds linked to increased risk of cognitive decline. Nat Rev Neurol. 2016;12(8):432–3.
   PubMedGoogle Scholar
• Simó M, Rifà-Ros X, Rodriguez-Fornells A, Bruna J. Chemobrain: A systematic review of structural and functional neuroimaging studies. Neurosci Biobehav Rev. 2013;37(8):1311–21.
   PubMed Web of Science ®Google Scholar
• Li M, Caeyenberghs K. Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: A systematic review. Neurosci Biobehav Rev. May 2018;92:304–317.
   PubMed Web of Science ®Google Scholar
• Partap S, Russo S, Esfahani B, Yeom K, Mazewski C, Embry L, Wheeler G, Ullrich NJ, Bowers DC. A Review of Chronic Leukoencephalopathy among Survivors of Childhood Cancer. Pediatr Neurol. 2019;101:2–31334.
   PubMed Web of Science ®Google Scholar
• Sleurs C, Deprez S, Emsell L, Lemiere J, Uyttebroeck A. Chemotherapy-induced neurotoxicity in pediatric solid non-CNS tumor patients: An update on current state of research and recommended future directions. Crit Rev Oncol Hematol. 2016;103:37–48.
   PubMed Web of Science ®Google Scholar
• Rollins N, Winick N, Bash R, Booth T. Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. AJNR Am J Neuroradiol. 2004;25(10):1688–95.
   PubMed Web of Science ®Google Scholar
• Kesler SR, Blayney DW. Neurotoxic effects of anthracycline- vs nonanthracycline-based chemotherapy on cognition in breast cancer survivors. JAMA Oncol. 2016;2(2):185–92.
   PubMed Web of Science ®Google Scholar
• Yang M, Moon C. Neurotoxicity of cancer chemotherapy. Neural Regen Res. 2013;8(17):1606–14.
   PubMed Web of Science ®Google Scholar
• Cole PD, Kamen BA. Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia. Ment Retard Dev Disabil Res Rev. 2006;12(3):174–83.
   PubMedGoogle Scholar
• Reddick WE, Glass JO, Helton KJ, Langston JW, Xiong X, Wu S, Pui C-H. Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. AJNR Am J Neuroradiol. 2005;26(5):1263–9.
   PubMed Web of Science ®Google Scholar
• Suzuki D, Kobayashi R, Iguchi A, Sano H, Kishimoto K, Yasuda K, Kobayashi K. Tumor lysis syndrome as a risk factor for posterior reversible encephalopathy syndrome in children with hematological malignancies. Int J Hematol. 2014;100(5):485–9.
   PubMed Web of Science ®Google Scholar
• Tsujimoto S-I, Yanagimachi M, Tanoshima R, Urayama KY, Tanaka F, Aida N, Goto H, Ito S. Influence of ADORA2A gene polymorphism on leukoencephalopathy risk in MTX-treated pediatric patients affected by hematological malignancies. Pediatr Blood Cancer. 2016;63(11):1983–9.
   PubMed Web of Science ®Google Scholar
• Ziereisen F, Dan B, Azzi N, Ferster A, Damry N, Christophe C. Reversible acute methotrexate leukoencephalopathy: atypical brain MR imaging features. Pediatr Radiol. 2006;36(3):205–12.
   PubMed Web of Science ®Google Scholar
• Kingma A, Van Dommelen RI, Mooyaart EL, Wilmink JT, Deelman BG, Kamps WA. Slight cognitive impairment and magnetic resonance imaging abnormalities but normal school levels in children treated for acute lymphoblastic leukemia with chemotherapy only. J Pediatr. 2001;139(3):413–20.
   PubMed Web of Science ®Google Scholar
• Hertzberg H, Huk WJ, Ueberall MA, Langer T, Meier W, Dopfer R, et al. CNS late effects after ALL therapy in childhood. Part I: Neuroradiological findings in long-term survivors of childhood ALL–an evaluation of the interferences between morphology and neuropsychological performance. The German Late Effects Working Group. Med Pediatr Oncol. 1997;28(6):387–400.
   PubMedGoogle Scholar
• Mahoney DH, Shuster JJ, Nitschke R, Lauer SJ, Steuber CP, Winick N, Camitta B. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy–a Pediatric Oncology Group study. JCO. 1998;16(5):1712–22.
   PubMed Web of Science ®Google Scholar
• Baytan B, Evim MS, Güler S, Güneş AM, Okan M. Acute Central Nervous System Complications in Pediatric Acute Lymphoblastic Leukemia. Pediatr Neurol. 2015;53(4):312–8.
   PubMed Web of Science ®Google Scholar
• Bhojwani D, Sabin ND, Pei D, Yang JJ, Khan RB, Panetta JC, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014;32(9):949–59.
   PubMed Web of Science ®Google Scholar
• Cheung YT, Sabin ND, Reddick WE, Bhojwani D, Liu W, Brinkman TM, et al. Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis. Lancet Haematol. 2016;3(10):e456–e466.
   PubMed Web of Science ®Google Scholar
• Sabin ND, Cheung YT, Reddick WE, et al. The impact of persistent leukoencephalopathy on brain white matter microstructure in long-term survivors of acute lymphoblastic leukemia treated with chemotherapy only. Am J Neuroradiol. 2018;39(10):1919–1925.
   PubMed Web of Science ®Google Scholar
• Cole PD, Beckwith KA, Vijayanathan V, Roychowdhury S, Smith AK, Kamen BA. Folate homeostasis in cerebrospinal fluid during therapy for acute lymphoblastic leukemia. Pediatr Neurol. 2009;40(1):34–41.
   PubMed Web of Science ®Google Scholar
• Duffner PK, Armstrong FD, Chen L, Helton KJ, Brecher ML, Bell B, et al. Neurocognitive and neuroradiologic central nervous system late effects in children treated on Pediatric Oncology Group (POG) P9605 (Standard Risk) and P9201 (Lesser Risk) Acute Lymphoblastic Leukemia Protocols (ACCL0131). J Pediatr Hematol Oncol. 2014;36(1):8–15.
   PubMed Web of Science ®Google Scholar
• Nassar SL, Conklin HM, Zhou Y, Ashford JM, Reddick WE, Glass JO, et al. Neurocognitive outcomes among children who experienced seizures during treatment for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2017;64(8):e26436.
   Web of Science ®Google Scholar
• Parasole R, Petruzziello F, Menna G, Mangione A, Cianciulli E, Buffardi S, et al. Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution. Leuk Lymphoma. 2010;51(6):1063–71.
   PubMed Web of Science ®Google Scholar
• Krull KR, Sabin ND, Reddick WE, Zhu L, Armstrong GT, Green DM, et al. Neurocognitive function and CNS integrity in adult survivors of childhood Hodgkin lymphoma. JCO. 2012;30(29):3618–24.
   PubMed Web of Science ®Google Scholar
• Choi SM, Lee SH, Yang YS, Kim BC, Kim MK, Cho KH. 5-fluorouracil-induced leukoencephalopathy in patients with breast cancer. J Korean Med Sci. 2001;16(3):328–34.
   PubMed Web of Science ®Google Scholar
• Baehring JM, Fulbright RK. Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients. J Neurol Neurosurg Psychiatry. 2008;79(5):535–9.
   PubMed Web of Science ®Google Scholar
• Khan SJ, Arshad AA, Fayyaz MB, Ud Din Mirza I. Posterior reversible encephalopathy syndrome in pediatric cancer: clinical and radiologic findings. J Glob Oncol. 2018;(4):1–8.
   Web of Science ®Google Scholar
• Lucchini G, Grioni D, Colombini A, Contri M, De Grandi C, Rovelli A, et al. Encephalopathy syndrome in children with hemato-oncological disorders is not always posterior and reversible. Pediatr Blood Cancer. 2008;51(5):629–33.
   PubMed Web of Science ®Google Scholar
• Belaramani KM, Lai V, Li CH, Lee ACW, Kwong NS. Reversible posterior leukoencephalopathy syndrome in Chinese children induced by chemotherapy: a review of five cases. Hong Kong Med J. 2011;17(1):61–6.
   PubMedGoogle Scholar
• Carson KR, Newsome SD, Kim EJ, Wagner-Johnston ND, von Geldern G, Moskowitz CH, et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer. 2014;120(16):2464–71.
   PubMed Web of Science ®Google Scholar
• Fitzgerald RT, Wright SM, Samant RS, Kumar M, Ramakrishnaiah RH, Van Hemert R, et al. Elevation of serum lactate dehydrogenase at posterior reversible encephalopathy syndrome onset in chemotherapy-treated cancer patients. J Clin Neurosci. 2014;21(9):1575–8.
   PubMed Web of Science ®Google Scholar
• Li H, Liu Y, Chen J, Tan X, Ye X-Y, Ma M-S, Huang J-P, Zou L-P. Posterior reversible encephalopathy syndrome in patients with hematologic tumor confers worse outcome. World J Pediatr. 2015;11(3):245–9.
   PubMed Web of Science ®Google Scholar
• Kamiya-Matsuoka C, Paker AM, Chi L, Youssef A, Tummala S, Loghin ME. Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study. J Neurooncol. 2016;128(1):75–84.
   PubMed Web of Science ®Google Scholar
• Kamiya-Matsuoka C, Tummala S. Electrographic patterns in patients with posterior reversible encephalopathy syndrome and seizures. J Neurol Sci. 2017;375:294–8.
   PubMed Web of Science ®Google Scholar
• Tang J-H, Tian J-M, Sheng M, Hu S-Y, Li Y, Zhang L-Y, Gu Q, Wang Q. Study of Posterior Reversible Encephalopathy Syndrome in Children With Acute Lymphoblastic Leukemia After Induction Chemotherapy. J Child Neurol. 2016;31(3):279–84.
   PubMed Web of Science ®Google Scholar
• Koppelmans V, Vernooij MW, Boogerd W, Seynaeve C, Ikram MA, Breteler MMB, Schagen SB. Prevalence of cerebral small-vessel disease in long-term breast cancer survivors exposed to both adjuvant radiotherapy and chemotherapy. J Clin Oncol. 2015;33(6):588–93.
   PubMed Web of Science ®Google Scholar
• Menning S, de Ruiter MB, Veltman DJ, Boogerd W, Oldenburg HSA, Reneman L, Schagen SB. Changes in brain white matter integrity after systemic treatment for breast cancer: a prospective longitudinal study. Brain Imaging Behav. 2018;12(2):324–34.
   PubMed Web of Science ®Google Scholar
• Sleurs C, Lemiere J, Radwan A, Verly M, Elens I, Renard M, et al. Long‐term leukoencephalopathy and neurocognitive functioning in childhood sarcoma patients treated with high‐dose intravenous chemotherapy. Pediatr Blood Cancer. 2019;66(10):e27893.
   PubMed Web of Science ®Google Scholar
• Ahles TA, Saykin AJ, McDonald BC, Li Y, Furstenberg CT, Hanscom BS, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. JCO. 2010;28(29):4434–40.
   PubMed Web of Science ®Google Scholar
• Blommaert J, Schroyen G, Vandenbulcke M, Radwan A, Smeets A, Peeters R, et al. Age‐dependent brain volume and neuropsychological changes after chemotherapy in breast cancer patients. Hum Brain Mapp. 2019;40(17):4994–5010.
   PubMed Web of Science ®Google Scholar
• Panis B, Vlaar AMM, van Well GTJ, Granzen B, Weber JW, Postma AA, et al. Posterior reversible encephalopathy syndrome in paediatric leukaemia. Eur J Paediatr Neurol. 2010;14(6):539–45.
   PubMed Web of Science ®Google Scholar
• Atra A, Pinkerton CR, Bouffet E, Norton A, Hobson R, Imeson JD, Gerrard M, United Kingdom Children Cancer Study Group/Non-Hodgkin Lymphoma Group. Acute Acute neurotoxicity in children with advanced stage B-non-Hodgkin's lymphoma and B-acute lymphoblastic leukaemia treated with the United Kingdom children cancer study group 9002/9003 protocols. Eur J Cancer. 2004;40(9):1346–50.
   PubMed Web of Science ®Google Scholar
• Sen A, Capelli V, Husain M. Cognition and dementia in older patients with epilepsy. Brain. 2018;141(6):1592–608.
   PubMedGoogle Scholar
• Deprez S, Vandenbulcke M, Peeters R, Emsell L, Smeets A, Christiaens M-R, et al. Longitudinal assessment of chemotherapy-induced alterations in brain activation during multitasking and its relation with cognitive complaints. JCO. 2014;32(19):2031–8.
   PubMed Web of Science ®Google Scholar
• Schuitema I, Deprez S, Van Hecke W, Daams M, Uyttebroeck A, Sunaert S, et al. Accelerated aging, decreased white matter integrity, and associated neuropsychological dysfunction 25 years after pediatric lymphoid malignancies. J Clin Oncol. 2013;31(27):3378–88.
   PubMed Web of Science ®Google Scholar
• Dietrich J, Han R, Yang Y, Mayer-Pröschel M, Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol. 2006;5(7):22.
   PubMedGoogle Scholar
• Horowitz TS, Suls J, Treviño M. A call for a neuroscience approach to cancer-related cognitive impairment. Trends Neurosci. 2018;41(8):493–6.
   PubMed Web of Science ®Google Scholar
• Billiet T, Emsell L, Vandenbulcke M, et al. Recovery from chemotherapy-induced white matter changes in young breast cancer survivors?. Brain Imaging Behav. January 2017;12(1):64–77.
   Web of Science ®Google Scholar
• Billiet T, Elens I, Sleurs C, Uyttebroeck A, D’Hooge R, Lemiere J, Deprez S. Brain connectivity and cognitive flexibility in nonirradiated adult survivors of childhood leukemia. JNCI J Natl Cancer Inst. 2018;110(8):905–13.
   Web of Science ®Google Scholar
• Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007;7(3):192–201.
   PubMed Web of Science ®Google Scholar
• Sleurs C, Madoe A, Lagae L, Jacobs S, Deprez S, Lemiere J, Uyttebroeck A. Genetic modulation of neurocognitive development in cancer patients throughout the lifespan: a systematic review. Neuropsychol Rev. 2019;29(2):190–219.
   PubMed Web of Science ®Google Scholar